HTB

Treatment access

Fixed dose combination efavirenz/tenofovir/FTC for South Africa

New UNAIDS report highlights progress in the AIDS response in Africa

Indian Supreme Court delivers verdict in Novartis case: decision safeguards access to affordable medicines and prevents abusive patenting of medicines

FDA approval of generic ARVs

New UNITAID grants focus on paediatric HIV, TB and malaria

Global Fund results continue upward trend

Germany extends €200 million annual support to Global Fund until 2016

New analysis of country pledges and contributions to the Global Fund

Renewal of Indian Global Fund Grant made conditional on government funding for ART

MSF and DNDi report highlights importance of research into neglected diseases

FDA approval of generic ARVs

d4T – time to move on

Global Fund provides ART for 4.2 million people: 2012 update

$84 million grant to Zimbabwe to reach universal access in 2012

Mark Dybul to be the next executive director of the Global Fund

US NIH to enforce open access to clincal trial results

FDA approval of generic ARVs

Free HIV treatment in the UK for all, irrespective of residency status

Robin Hood Tax begins in France

Novartis case enters Indian Supreme court

Online video interviews between researchers and activists

India: Bayer stay order against compulsory licence denied

IAS: social and political talks online as web casts

FDA approval of generic ARVs

Activists protest at IAS for Global Fund to stick to principles

EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines

US trade deal threatens access to medicines

Stavudine (d4T) phase-out festival in Delhi

FDA approval of generic ARVs: nevirapine and Combivir now off-patent in the US

Global action over the challenge to India

Why global health activists are fired up about Novartis

Obama’s global, domestic & HIV research budget backslides on existing commitments

FDA approval of generic ARVs

Disastrous warning for global HIV programmes in 2012

Janssen block Patent Pool access to darunavir, rilpivirine and etravrine

UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria

Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager

Call to Action on Global Fund restriction to new funding to 2014

Analysis of why the Global Fund cancelled Round 11

Reaction to the Global Fund's decisions on Round 11 and grant renewals

Activists oppose Gates Foundation funding study using low dose d4T

Global Fund cancels Round 11 and introduces new rules for grant renewals

FDA approval of generic ARVs

We need the Patent Pool to work

FDA approval of generic ARVs

Global Fund adopts restructuring recommendations and close to 50% funding shortfall for next round of grants

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

Gilead signs up for Medicines Patent Pool

FDA approval of generic ARVs

Patents and the pipeline: is access under threat?

An audit of HIV care provision for Immigration Removal Centre patients

FDA approval of generic ARVs

Global Fund reports rise in people on treatment

UK increases funding to the Global Fund

UK government development priorities and HIV

Update on the Patent Pool

TRIPS agreement flexibilities provide opportunities for improved access to ARVs

Driving a decade of change: HIV/AIDS, patents and access to medicines for all

FDA approval of generic ARVs

ART distribution and adherence support by community groups in Mozambique

Commentary: corruption by Global Fund grant implementers

Virological findings from the SARA trial ofboosted protease inhibitor monotherapy

Shortfall in funding for the Global Fund

Post navigation